Michael P. Lance, MD, FRCP

Dr. Lance was board certified in internal medicine and gastroenterology, and was consistently funded as a principal investigator by NIH/NCI, and earlier the Veterans Administration, since the early 1990s. He was PI of the University of Arizona Gastrointestinal Special Program of Research Excellence, leading research in early-onset colorectal cancers, and was PI of multi-institutional P01 and R01 grants that have funded two placebo-controlled Phase 3 colorectal adenoma chemoprevention trials investigating ursodeoxycholic acid and selenium supplement + celecoxib. An invaluable, meticulously archived biobank, now comprising ~250,000 biospecimens (tissues, plasma, genomic DNA, urine, feces, etc.), collected from participants in these trials (and an earlier trial of wheat bran fiber) was the platform for over 40 publications over five years; preliminary fecal microbiota and bile acid data for Project 1 in the current application were derived from UDCA trial participant fecal specimens.

Formerly, at Roswell Park Cancer Institute, Dr. Lance was contracted as a site PI for NCI’s Polyp Prevention Trial, led by Arthur Schatzkin, PhD.

During his time at the University of Arizona, Dr. Lance served as co-director of Cancer Prevention and Control and was director of the Arizona Clinical and Translational Research and Education Consortium, Tucson Program, at the University of Arizona Cancer Center. He also was deputy director of the University of Arizona Cancer Center, Phoenix.